

OTCQB Certification

I, A. Rachel Leheny, Chief Executive Officer of CalciMedica, Inc. (“the Company”), certify that:

1. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (mark the box below that applies with an “X”):

REGISTERED or REPORTING WITH THE SEC:

- Company is registered under Section 12(g) of the Exchange Act
 Company is reporting under Section 15(d) of the Exchange Act.
 Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
 Company is reporting under Regulation A (Tier 2)
 Other (describe) _____

EXEMPT FROM SEC REGISTRATION/NO SEC REPORTING OBLIGATIONS:

- Company is exempt from registration under Exchange Act Rule 12g3-2(b)
 Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
 Company is reporting under the Alternative Reporting Company Disclosure Guidelines and is otherwise exempt from registration and not required to file periodic reporting

2. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC’s EDGAR system or the OTC Disclosure & News Service, as applicable.
3. The company is duly organized, validly existing and in good standing under the laws of Delaware in which the Company is organized or does business.
4. The share information below is for the primary OTCQB traded security as of the latest practicable date:

US Trading Symbol		<u>CALC</u>
As of (date)		<u>3/31/2023</u>
Shares Authorized	(A)	<u>510,000,000</u>
Total Shares Outstanding	(B)	<u>5,661,933</u>
Number of Restricted Shares ¹	(C)	<u>4,469,636</u>
Unrestricted Shares Held by Officers, Directors, 10% Control Persons & Affiliates	(D)	<u>0</u>
Public Float: <i>Subtract Lines C and D from Line B</i>	(E)	<u>1,192,297</u>
% Public Float: <i>Line E Divided by Line B (as a %)</i> ²	(F)	<u>21.06%</u>

¹ Restricted Shares means securities that are subject to resale restrictions for any reason. Your transfer agent should be able to provide the total number of restricted securities.

² Public Float means the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a “10 percent Control Person”), or any Affiliates thereof, or any Family Members of officers, directors, and control persons. Family Member shall mean a Person’s spouse, parents, children, and siblings, whether by blood, marriage or adoption, or anyone residing in such Person’s home. OTCQB traded securities are required to have a freely traded public float of at least 10% of the shares outstanding unless an exemption applies.

Number of Beneficial Shareholders of at least 100 shares ³	(G)	524
---	-----	-----

5. Convertible Debt:

The following is a complete list of all promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities that were issued or outstanding at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification. **(If the note is no longer outstanding as of the current date, but was outstanding during the previously described timeframe, the note must still be disclosed in the table below.):**

Check this box if there were no promissory notes, convertible notes, or other convertible debt arrangements issued or outstanding at any point during this time period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) ⁴	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ^{5(B)}	Name of Noteholder (entities must have individual with voting / investment control disclosed). ⁶	Reason for Issuance (e.g., Loan, Services, etc.)
4/22/2022	\$3,142.88	\$ -	12/31/2023	(A)	143,073	-	STMC II, LLC	Loan/Capital Investment
4/22/2022	\$5,457.53	\$ -	12/31/2023	(A)	248,443	-	Robert N. Wilson	Loan/Capital Investment
4/22/2022	\$5,393.08	\$ -	12/31/2023	(A)	245,509	-	Sanderling Ventures VII (Canada), L.P.	Loan/Capital Investment
4/22/2022	\$1,393.20	\$ -	12/31/2023	(A)	63,422	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment
4/22/2022	\$20,501.39	\$ -	12/31/2023	(A)	933,285	-	Sanderling Ventures VII, L.P.	Loan/Capital Investment
5/10/2022	\$2,807.74	\$ -	12/31/2023	(A)	134,764	-	Mark Hubbard	Loan/Capital Investment
5/13/2022	\$142.61	\$ -	12/31/2023	(A)	6,907	-	WS Investment Company, LLC (22A)	Loan/Capital Investment
5/19/2022	\$611.61	\$ -	12/31/2023	(A)	30,179	-	Alma Life Sciences, LLC	Loan/Capital Investment
5/19/2022	\$ 2,887.28	\$ -	12/31/2023	(A)	142,471	-	STMC II, LLC	Loan/Capital Investment
6/7/2022	\$4,318.99	\$ -	12/31/2023	(A)	226,600	-	Bering Partners II, L.P.	Loan/Capital Investment
6/7/2022	\$5,446.96	\$ -	12/31/2023	(A)	285,780	-	Valence Investments SPV VI, LLC	Loan/Capital Investment
6/9/2022	\$646.47	\$ -	12/31/2023	(A)	34,145	-	IRA Financial Trust Company CFBO Eric W Roberts	Loan/Capital Investment
6/10/2022	\$2,128.10	\$ -	12/31/2023	(A)	112,783	-	Mesa Verde Venture Partners III, LP	Loan/Capital Investment
6/13/2022	\$469.99	\$ -	12/31/2023	(A)	25,162	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment

³ Beneficial Shareholder means any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security. OTCQB traded securities are required to have at least 50 beneficial shareholders unless an exemption applies.

⁴ The Outstanding Balance is to include accrued interest.

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

⁶ International Reporting Companies may elect not to disclose the names of noteholders who are non-affiliates of the company. "Affiliate" is a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, an officer, a director, or a shareholder beneficially owning 10 percent or more of the Company's outstanding shares.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$)⁴	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion⁵(⁶)	Name of Noteholder (entities must have individual with voting / investment control disclosed).⁶	Reason for Issuance (e.g., Loan, Services, etc.)
6/14/2022	\$6,891.42	\$ -	12/31/2023	(A)	370,229	-	Sanderling Ventures VII, L.P.	Loan/Capital Investment
6/15/2022	\$1,806.38	\$ -	12/31/2023	(A)	97,378	-	Sanderling Ventures VII (Canada), LP	Loan/Capital Investment
6/21/2022	\$409.08	\$ -	12/31/2023	(A)	22,517	-	Golden Triangle Ventures, LLC	Loan/Capital Investment
7/14/2022	\$2,753.04	\$ -	12/31/2023	(A)	164,940	-	Robert N. Wilson	Loan/Capital Investment
7/14/2022	\$626.95	\$ -	12/31/2023	(A)	37,561	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment
7/14/2022	\$9,225.63	\$ -	12/31/2023	(A)	552,726	-	Sanderling Ventures VII, LP	Loan/Capital Investment
7/14/2022	\$7,963.63	\$ -	12/31/2023	(A)	477,117	-	Valence Investments SPV VI, LLC	Loan/Capital Investment
7/15/2022	\$2,417.12	\$ -	12/31/2023	(A)	145,375	-	Sanderling Ventures VII (Canada), LP	Loan/Capital Investment
8/2/2022	\$3,736.17	\$ -	12/31/2023	(A)	241,605	-	Sanderling Ventures VII (Canada), LP	Loan/Capital Investment
8/2/2022	\$14,202.77	\$ -	12/31/2023	(A)	918,446	-	Sanderling Ventures VII, LP	Loan/Capital Investment
8/2/2022	\$965.17	\$ -	12/31/2023	(A)	62,414	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment
8/17/2022	\$236.33	\$ -	12/31/2023	(A)	16,309	-	IRA Financial Trust Company CFBO Eric W Roberts	Loan/Capital Investment
8/17/2022	\$2,851.15	\$ -	12/31/2023	(A)	196,769	-	Robert N. Wilson	Loan/Capital Investment
8/17/2022	\$5,298.26	\$ -	12/31/2023	(A)	365,654	-	Valence Investments SPV VI, LLC	Loan/Capital Investment
8/25/2022	\$14,959.64	\$ -	12/31/2023	(A)	1,070,962	-	Quark Ventures Inc.	Loan/Capital Investment
10/12/2022	\$6.44	\$ -	12/31/2023	(A)	595	-	Katherine McNeil	Loan/Capital Investment
10/6/2022	\$397.82	\$ -	12/31/2023	(A)	35,490	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment
10/6/2022	\$1,539.95	\$ -	12/31/2023	(A)	137,384	-	Sanderling Ventures VII (Canada), LP	Loan/Capital Investment
10/6/2022	\$5,853.99	\$ -	12/31/2023	(A)	522,254	-	Sanderling Ventures VII, LP	Loan/Capital Investment
11/21/2022	\$26,216.09	\$ -	12/31/2023	(A)	3,219,037	-	Valence Investments SPV VI, LLC	Loan/Capital Investment
11/21/2022	\$844.18	\$ -	12/31/2023	(A)	103,656	-	IRA Financial Trust Company CFBO Eric W Roberts	Loan/Capital Investment
11/21/2022	\$9,780.82	\$ -	12/31/2023	(A)	1,200,973	-	Robert N. Wilson	Loan/Capital Investment
11/21/2022	\$9,780.82	\$ -	12/31/2023	(A)	1,200,973	-	Henry A. Mckinnell Revocable Trust	Loan/Capital Investment
11/21/2022	\$3,128.32	\$ -	12/31/2023	(A)	384,121	-	Sanderling Ventures VII, L.P.	Loan/Capital Investment
11/21/2022	\$820.92	\$ -	12/31/2023	(A)	100,800	-	Sanderling Ventures VII (Canada), L.P.	Loan/Capital Investment
11/21/2022	\$212.07	\$ -	12/31/2023	(A)	26,039	-	Sanderling Ventures VII Annex Fund, L.P.	Loan/Capital Investment
11/21/2022	\$21,920.88	\$ -	12/31/2023	(A)	2,691,634	-	Sanderling Venture Partners VI Co-Investment Fund, L.P.	Loan/Capital Investment
11/21/2022	\$26,082.19	\$ -	12/31/2023	(A)	3,202,595	-	Revelation Healthcare Fund I, L.P.	Loan/Capital Investment
11/21/2022	\$1,956.16	\$ -	12/31/2023	(A)	240,194	-	Mesa Verde Venture Partners III, LP	Loan/Capital Investment
11/21/2022	\$397.71	\$ -	12/31/2023	(A)	48,834	-	Alma Life Sciences, LLC	Loan/Capital Investment

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$)⁴	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion⁵(B)	Name of Noteholder (entities must have individual with voting / investment control disclosed).⁶	Reason for Issuance (e.g., Loan, Services, etc.)
	Total Outstanding Balance:	\$ -		Total Shares:	20,487,104	-		

Use the space below to provide any additional details, including footnotes to the table above:

(A) Immediately prior to the effective time of the Merger, the above-listed convertible promissory notes (the “2022 Notes”) converted into shares of CalciMedica common stock at a conversion price based on the equivalent valuation of the cash price paid per share by the private placement investors purchasing shares of CalciMedica common stock in the private placement multiplied by 0.85. Such shares of CalciMedica Subsidiary, Inc. (f/k/a CalciMedica, Inc.) common stock were then converted into shares of the Company’s common stock at the effective time of the Merger in accordance with the Merger Agreement, as reported in Item 5.02 to Form 8-K, filed with the SEC on March 22, 2023.

(B) On March 20, 2023, all of the 2022 Notes converted into the Company’s common stock, as reported in Item 2.01 to Form 8-K, filed with the SEC on March 22, 2023.

6. The following is a complete list of any law firm(s) and attorney(s) that acted as the Company’s primary legal counsel in preparing its most recent annual report. **Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel.** (If no attorney assisted in putting together the disclosure, identify the person(s) who prepared the disclosure and their relationship to the company.) Please also identify any other attorney, if different than the primary legal counsel, that assisted the company during the prior fiscal year on any matter including but not limited to, preparation of disclosure, press releases, consulting services, corporate action or merger assistance, etc.

Cooley LLP: Carlos Ramirez, 858-550-6157, cramirez@cooley.com

Fenwick & West LLP: Julia Forbess, 415-875-2420, jforbess@fenwick.com

7. The following is a complete list of third-party providers, engaged by the Company, its officers, directors or controlling shareholders, at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, consulting, stock promotion, or any other related services to the Company. **Please include the following items in this list: firm name, firm address, primary contact name and description of services provided.** If none, please state “None”.

Argot Partners: Sarah Sutton/Kevin Murphy, 212-600-1902, calcimedica@argotpartners.com, public relations.

ICR Westwicke: Robert Uhl, Managing Director, 800-210-2491, robert.uhl@westwicke.com, public relations.

8. Officers, Directors and 5% Control Persons:

The following is a complete list of Officers, Directors and 5% Control Persons (control persons are beneficial owners of five percent (5%) or more of any class of the issuer’s equity securities), including name, address, and number of shares owned. Preferred shares, options, warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. **If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities. If the corporate entity owning 5% or more does not have a person(s) owning or controlling it, provide a note explaining why. For nominee accounts owning 5% or more, provide the name of the 5% beneficial shareholder for this account. If there are no beneficial shareholders of 5% or more behind a nominee account, add a note confirming this.**

Name (First, Last)	Position/company affiliation	City and State	Number of Shares Owned	Class of shares owned	Percentage of Class of
--------------------	------------------------------	----------------	------------------------	-----------------------	------------------------

	(ex: CEO, 5% control person)	(and Country if outside US)	(list common, preferred, warrants and options separately) ^(A)		Shares Owned (undiluted) ^(A)
Wilson, Robert N.	Chair of the Board	New Hope, PA	181,655	shares of Common Stock	3.2921%
Wilson, Robert N.	Chair of the Board	New Hope, PA	27,947	options to purchase Common Stock	N/A
Wilson, Robert N.	Chair of the Board	New Hope, PA	17,184	warrants to purchase Common Stock	N/A
Middleton, Fred	Director	San Mateo, CA	8,176	shares of Common Stock ^(1A)	0.2003%
Middleton, Fred	Director	San Mateo, CA	2,880	warrants to purchase Common Stock ^(1B)	N/A
Shaw, Allan	Director	Rye Brook, NY	1,891	options to purchase Common Stock	0.0343%
Bjerkholt, Eric	Director	Berkeley, CA	1,429	restricted stock units	0.0538%
Bjerkholt, Eric	Director	Berkeley, CA	1,543	options to purchase common stock	N/A
Guerard, Frederic	Director	Austin, TX	27,405	shares of Common Stock;	3.8120%
Guerard, Frederic	Director	Austin, TX	83,705	restricted stock units;	N/A
Guerard, Frederic	Director	Austin, TX	106,484	options to purchase Common Stock.	N/A
Leheny, A. Rachel	CEO and Director	La Jolla, CA	163,782	options to purchase Common Stock ⁽²⁾	2.8826%
Roberts, Eric W.	CBO and Director	Millerton, NY	10,661	shares of Common Stock ⁽³⁾	1.6481%
Roberts, Eric W.	CBO and Director	Millerton, NY	79,954	options to purchase Common Stock	N/A
Roberts, Eric W.	CBO and Director	Millerton, NY	1,513	warrants to purchase Common Stock;	N/A
Dunn, Michael J.	President and COO	La Jolla, CA	87,549	options to purchase Common Stock	1.5618%
Geffken, Daniel	Interim CFO	Cambridge, MA	16,862	warrants to purchase Common Stock ⁽⁴⁾	0.3048%
Hebbar, Sudarshan	CMO	Bluffton, SC	118,169	options to purchase Common Stock	2.0966%
Stauderman, Kenneth A.	CSO	San Diego, CA	11,944	shares of Common Stock	1.6116%
Stauderman, Kenneth A.	CSO	San Diego, CA	78,242	options to purchase Common Stock	N/A
Entities or Persons affiliated with Sanderling Ventures	5% holder	San Mateo, CA	1,640,044	shares of Common Stock ⁽⁵⁾	30.9503%
Entities or Persons affiliated with Sanderling Ventures	5% holder	San Mateo, CA	74,395	warrants to purchase Common Stock ⁽⁶⁾	N/A
Entities or Persons affiliated with Valence Investments SPV IV, LLC ⁽⁹⁾	5% holder	New York, NY	739,326	shares of Common Stock ⁽⁷⁾	13.7530%
Entities or Persons affiliated with Valence Investments SPV IV, LLC ⁽⁹⁾	5% holder	New York, NY	19,870	warrants to purchase Common Stock ⁽⁸⁾	N/A
Revelation Healthcare Fund I, L.P. ⁽¹⁰⁾	5% holder	Sausalito, CA	542,029	shares of Common Stock	9.8551%
Revelation Healthcare Fund I, L.P. ⁽¹⁰⁾	5% holder	Sausalito, CA	1,965	warrants to purchase Common Stock	N/A
Entities affiliated with Deerfield Management Company, L.P	5% holder	New York, NY	377,264	shares of Common Stock ⁽¹¹⁾	6.8370%
Entities affiliated with OrbiMed Advisors, LLC	5% holder	New York, NY	297,381	shares of Common Stock ⁽¹²⁾	5.3893%

Use the space below to provide any additional details, including conversion terms of any class of the issuer's equity securities:

(A) All shares of Common Stock reported are held as of March 20, 2023. All restricted stock units, options to purchase common stock and warrants reported are exercisable as of May 19, 2023. Percentage of Class of Shares Owned (undiluted) is based on the number of shares outstanding as of March 20, 2023, which was 5,517,973.

(1A) Held by Golden Triangle Ventures, LLC, which is controlled by Fred Middleton, its managing member, 1300 S El Camino Real, Suite 203, San Mateo, CA 94402.

(1B) Excludes securities held by Entities or Persons affiliated with Sanderling Ventures, that Mr. Middleton beneficially owns.

(2) Excludes securities held by Entities or Persons affiliated with Valence Investments SPV IV, LLC, that Dr. Leheny beneficially owns.

(3) Held by IRA Financial Trust Company CFBO Eric W Roberts. Excludes securities held by Entities or Persons affiliated with Valence Investments SPV IV, LLC, that Mr. Roberts beneficially owns. The address of Mr. Roberts and IRA Financial Trust Company CFBO Eric W Roberts is 23 Charlie Hill Rd., Millerton, NY 12546.

(4) Consists of 16,862 shares that SG Dan Equity Holdings, LLC has the right to acquire pursuant to the exercise of warrants. Mr. Geffken has voting or dispositive power with respect to warrants held by Danforth and SG Dan Equity Holdings, LLC and its address is 91 Middle Road, Southborough, MA 01772.

(5) Consists of (i) 582,757 shares held by Sanderling Venture Partners VI Co-Investment Fund, L.P.; (ii) 703,388 shares held by Sanderling Venture Partners VI, L.P.; (iii) 17,682 shares held by Sanderling Ventures Management VI; (iv) 1,548 shares held by Sanderling Ventures Management VII; (v) 47,052 shares held by Sanderling Ventures VII (Canada), L.P.; (vi) 14,425 shares held by Sanderling Ventures VII Annex Fund, L.P.; (vii) 256,852 shares held by Sanderling Ventures VII, L.P.; (viii) 7,456 shares held by Sanderling VI Beteligungs GmbH & Co KG; and (ix) 8,884 shares held by Sanderling VI Limited Partnership. The address of all of the foregoing entities is 1300 S El Camino Real, Suite 203, San Mateo, CA 94402.

(6) Consists of (i) 24,165 shares that Sanderling Venture Partners VI Co-Investment Fund, L.P. has the right to acquire pursuant to the exercise of warrants; (ii) 21,896 shares that Sanderling Venture Partners VI, L.P. has the right to acquire pursuant to the exercise of warrants; (iii) 420 shares that Sanderling Ventures Management VI has the right to acquire pursuant to the exercise of warrants; (iv) 280 shares that Sanderling Ventures Management VII has the right to acquire pursuant to the exercise of warrants; (v) 5,452 shares that Sanderling Ventures VII (Canada), LP has the right to acquire pursuant to the exercise of warrants; (vi) 1,409 shares that Sanderling Ventures VII Annex Fund, L.P. has the right to acquire pursuant to the exercise of warrants; (vii) 20,773 shares that Sanderling Ventures VII, LP has the right to acquire pursuant to the exercise of warrants. The address of all of the foregoing entities is 1300 S El Camino Real, Suite 203, San Mateo, CA 94402.

(7) Consists of (i) 356,989 shares held by Valence Investments SPV IV, LLC, (ii) 66,228 shares held by Valence Investments SPV V, LLC and (iii) 316,109 shares held by Valence Investments SPV VI, LLC.

(8) Held by Valence Investments SPV V, LLC.

(9) Dr. Leheny and Mr. Roberts are the co-founders and managing directors of Valence IV, Valence V and Valence VI, have shared voting and dispositive power with respect to shares held by such entities, and disclaim beneficial ownership of such shares except to the extent of his or her respective pecuniary interest therein. The principal business address of Valence Investment LLC is 590 Madison Avenue, 21st Floor, New York, NY 10022.

(10) Securities are held by Revelation Healthcare Fund I, L.P. (Revelation). Scott Halsted is a managing member at Revelation. Mr. Halsted has voting or dispositive power with respect to shares held by Revelation and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of Revelation is 300 Turney Street, 2nd Floor, Sausalito, CA 94965.

(11) Consists of (i) 122,419 shares held by Deerfield Private Design Fund III, (ii) 132,426 shares held by Deerfield Partners and (iii) 122,419 shares held by Deerfield Healthcare Innovations Fund. Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P., Deerfield Mgmt. HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. and Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. Deerfield Management Company, L.P. is the investment manager of each of Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Partners, L.P. Mr. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. and Mr. James E. Flynn may be deemed to beneficially own the securities held by Deerfield Private Design Fund III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P. The address of each of Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Partners, L.P. is c/o Deerfield Management Company, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017.

(12) Consists of 297,381 shares held by OrbiMed Private Investments VI, L.P. (OPI VI). OrbiMed Capital GP VI LLC (OrbiMed GP) is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI, and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the shares held by OPI VI and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. Also consists of 5,250 shares held by BIOG, a publicly-listed investment trust organized under the laws of England. OrbiMed Capital LLC (OrbiMed Capital) is the investment advisor of BIOG. As a result, OrbiMed Capital has the power to direct the vote and disposition of the shares held by BIOG and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner of the shares held by BIOG. OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by BIOG. The address of OrbiMed Advisors is 601 Lexington Avenue, 54th Floor, New York, NY 10022.

9. Certification:

Date: April 17, 2023

Name of Certifying CEO or CFO: A. Rachel Leheny, Ph.D.

Title: Chief Executive Officer

Signature: /s/ A. Rachel Leheny, Ph.D.

(Digital Signatures should appear as "/s/ [OFFICER NAME]")